A detailed history of Summit Global Investments transactions in Mannkind Corp stock. As of the latest transaction made, Summit Global Investments holds 13,901 shares of MNKD stock, worth $91,468. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,901
Previous 13,901 -0.0%
Holding current value
$91,468
Previous $73,000 19.18%
% of portfolio
0.01%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

Jan 27, 2022

SELL
$3.14 - $6.14 $1,428 - $2,793
-455 Reduced 3.17%
13,901 $54,000
Q4 2019

Feb 13, 2020

BUY
$1.14 - $1.49 $16,365 - $21,390
14,356 New
14,356 $19,000
Q3 2019

Nov 08, 2019

SELL
$1.04 - $1.44 $14,457 - $20,017
-13,901 Closed
0 $0
Q2 2019

Aug 16, 2019

BUY
$1.09 - $1.88 $15,152 - $26,133
13,901 New
13,901 $16,000
Q1 2019

May 14, 2019

SELL
$1.14 - $2.25 $16,365 - $32,301
-14,356 Closed
0 $0
Q3 2018

Nov 15, 2018

BUY
$1.01 - $2.19 $14,499 - $31,439
14,356 New
14,356 $26,000

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.69B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Summit Global Investments Portfolio

Follow Summit Global Investments and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Global Investments, based on Form 13F filings with the SEC.

News

Stay updated on Summit Global Investments with notifications on news.